Marosi Christine
Division of Medical Oncology, Department of Internal Medicine I, Medical University Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
Wien Med Wochenschr. 2006 Jun;156(11-12):346-50. doi: 10.1007/s10354-006-0307-4.
Concomitant and adjuvant treatment with Temozolomide, an oral alkylating agent, has significantly improved the survival of patients with newly diagnosed glioblastoma multiforme (study EORTC 26981/22981, NCIC CE3). When given with the appropriate cautiousness including weekly clinical and laboratory controls during the concomitant phase, this therapy is generally well tolerated. The observed toxicity is mainly haematological. Grade III and IV toxicities mainly thrombocytopenia or lymphocytopenia occur in around 5 % of patients. A prophylaxis against pneumocystis carinii pneumonia was mandatory in the EORTC study. Most importantly, the quality of life of the patients was maintained throughout the therapy. This success has boosted the whole field of neurooncology, after a dry spell of more than thirty years for glioblastoma multiforme. Whether this concept will be applicable to other brain tumours and which schedule modifications or combinations with biologicals will improve the effectivity of therapy in brain tumours should be explored in further studies.
口服烷化剂替莫唑胺进行同步和辅助治疗，显著提高了新诊断多形性胶质母细胞瘤患者的生存率（研究EORTC 26981/22981，NCIC CE3）。在同步治疗阶段给予适当的谨慎措施，包括每周进行临床和实验室检查时，这种治疗一般耐受性良好。观察到的毒性主要是血液学方面的。III级和IV级毒性主要为血小板减少或淋巴细胞减少，约5%的患者会出现。在EORTC研究中，预防卡氏肺孢子虫肺炎是必需的。最重要的是，患者的生活质量在整个治疗过程中得以维持。在多形性胶质母细胞瘤经历了三十多年的停滞期后，这一成功推动了整个神经肿瘤学领域的发展。这种理念是否适用于其他脑肿瘤，以及哪种方案调整或与生物制剂联合使用将提高脑肿瘤治疗的有效性，应在进一步研究中进行探索。
